OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice